Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib plus cardunilimab for advanced hepatocellular carcinoma after first-line therapy
ChiCTR2300077787Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and cadonilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective response rate (ORR). Started Nov 2023; status: recruiting.
02
Drugs
donafenibcadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300077787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077787.